Guardant Health prelim Q4 revenue rises 39%, beats expectations
I'm PortAI, I can summarize articles.
Guardant Health's preliminary Q4 revenue rose 39% to $280 million, surpassing analyst expectations of $267.82 million. The company reported a 38% increase in oncology test volumes, driven by innovations and commercial execution. Shield screening tests increased significantly, from 6,400 to 38,000. Analysts maintain a "buy" rating on the stock, with a median 12-month price target of $120.00, reflecting an 8.9% upside from its recent closing price of $110.17.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments